Takeda’s zasocitinib shows high clearance rates at difficult psoriasis sites

Takeda Pharmaceutical Company Limited (TSE: 4502; NYSE: TAK) has reported new Phase 3 data showing that investigational oral TYK2 inhibitor zasocitinib cleared or almost cleared psoriasis affecting the scalp, palms and soles in 69% to 77% of assessed patients at week 16. The secondary endpoint findings came from the pivotal LATITUDE PsO 3001 and LATITUDE PsO 3002 studies, which enrolled a combined 1,801 adults with moderate-to-severe plaque psoriasis across 21 countries. Scalp and palmoplantar response rates were higher than those recorded with placebo and apremilast, while nail disease improved significantly versus placebo. The results strengthen Takeda’s effort to position zasocitinib as a once-daily oral treatment capable of narrowing the efficacy gap between pills and injectable biologics. However, the medicine remains unapproved, and its commercial value will depend on regulatory assessment, final safety labelling, pricing, reimbursement and adoption in a crowded psoriasis market.

What did the LATITUDE PsO studies show at difficult and high-impact psoriasis sites?

LATITUDE PsO 3001 and LATITUDE PsO 3002 were global, randomised, double-blind studies controlled against both placebo and the oral psoriasis medicine apremilast. The trials enrolled 693 and 1,108 participants, respectively, and their primary analysis had already established that zasocitinib met the co-primary endpoints of clear or almost clear skin and at least a 75% improvement in the Psoriasis Area and Severity Index at week 16.

The latest analysis focused on patients whose disease affected areas that can be particularly difficult to manage. Among participants with at least moderate scalp involvement at baseline, 77% and 74% of zasocitinib recipients achieved a scalp-specific Physician Global Assessment score of clear or almost clear at week 16. The corresponding rates were 7% and 13% with placebo and 42% and 30% with apremilast. The differences between zasocitinib and both comparators were statistically significant.

Scalp psoriasis was present in 38% and 28% of the respective study populations, making this a meaningful subgroup rather than a narrowly selected analysis. The consistency between the two trials also reduces the risk that the result reflects an isolated outcome from one study.

Among patients with palmoplantar psoriasis, which affects the hands and feet, clear or almost clear response rates reached 71% and 69% with zasocitinib. Placebo produced rates of 22% and 10%, while apremilast produced 44% and 43%. Palmoplantar disease affected 24% and 22% of participants at baseline. Takeda characterised these response rates as numerically higher than the comparators, so the result should not be presented as a confirmed statistical superiority claim without the complete endpoint analysis.

Nail psoriasis was present in 37% and 30% of participants. Zasocitinib produced statistically significant improvements in Nail Psoriasis Severity Index scores versus placebo at week 16, with a probability value below 0.001. Takeda did not disclose the absolute average reduction in the public announcement, limiting the ability to assess the clinical magnitude from the probability value alone. Responses across the scalp, palms, soles and nails were sustained through week 24 in both studies.

Why do scalp, nail, palm and sole responses matter beyond headline PASI scores?

Overall PASI scores can understate the burden of psoriasis concentrated in small but high-impact areas. The scalp may affect appearance, confidence and social interaction, while nail disease can cause pain and interfere with hand function. Disease on the palms and soles can disrupt walking, manual work and routine activities despite covering a relatively small proportion of the body.

That makes site-specific clearance commercially and clinically relevant. A treatment capable of controlling visible and functionally important areas could improve patient satisfaction even when the change in total body surface area appears modest. It may also give clinicians another reason to consider systemic treatment for patients whose conventional severity measures do not fully capture their daily burden.

The new results therefore add information that the original whole-body endpoints could not provide. They suggest that zasocitinib’s overall efficacy was not driven only by improvement in easier-to-treat plaques on the torso or limbs. Consistent responses across anatomically different sites support Takeda’s proposed whole-body treatment profile.

The remaining evidence gap is patient-reported benefit. Clearance scores show what investigators observed, but commercial differentiation would be stronger if Takeda can connect those changes with improvements in pain, mobility, work productivity, sleep and quality of life.

How does zasocitinib compare with apremilast and the wider oral psoriasis market?

The direct comparison with apremilast is important because it establishes that zasocitinib’s convenience does not need to be assessed only against placebo. In the previously reported overall results, approximately 69% to 71% of zasocitinib recipients achieved clear or almost clear skin at week 16, compared with roughly 30% to 32% for apremilast. PASI 90 responses reached 52% to 61% with zasocitinib, versus about 16% to 17% with apremilast.

Complete skin clearance also favoured zasocitinib. PASI 100 rates were 33.4% and 25.2% in the two trials, compared with 2.9% and 4.3% for apremilast. The difficult-site analysis extends that efficacy advantage to scalp and palmoplantar response rates, although the strength of the statistical evidence differs by endpoint.

The more strategically important oral comparison may be with Bristol Myers Squibb’s deucravacitinib. Takeda reported in June that zasocitinib met the primary and key secondary endpoints in the separate LATITUDE Atlas head-to-head Phase 3 study. More than 35% of zasocitinib-treated patients achieved complete skin clearance at week 16, according to the topline disclosure, more than 2.5 times the rate recorded with deucravacitinib.

That result could help Takeda argue that zasocitinib represents more than another oral alternative. However, investors and prescribers will need the complete Atlas dataset, including baseline characteristics, detailed safety findings, discontinuations and longer-term durability, before judging the extent of differentiation.

Injectable biologics remain another competitive benchmark. Several established products offer high levels of skin clearance and extensive real-world experience. Zasocitinib’s opportunity is therefore not simply to outperform older oral therapy. It must offer enough efficacy to persuade patients and physicians that the convenience of a pill does not require an unacceptable compromise in disease control.

Does TYK2 selectivity give Takeda a differentiated safety and efficacy profile?

Zasocitinib is designed to inhibit tyrosine kinase 2, an enzyme involved in immune pathways associated with psoriasis and other inflammatory diseases. Takeda reports that the compound has more than one-million-fold selectivity for TYK2 over other Janus kinase enzymes in laboratory testing.

That selectivity supports the scientific rationale for targeting inflammation while limiting unwanted effects associated with broader pathway inhibition. It does not, by itself, demonstrate superior clinical safety. Regulators will assess observed adverse events, exposure duration, laboratory findings and potential class-related risks rather than relying solely on in vitro selectivity.

Through week 16 of the pivotal psoriasis studies, treatment-emergent adverse events occurred in 62.1% of zasocitinib recipients, compared with 46.9% for placebo and 50.5% for apremilast. Serious treatment-emergent adverse events occurred in 3.0%, less than 1% and 1.5%, respectively. The most common events with zasocitinib were upper respiratory tract infection, nasopharyngitis and acne.

Takeda said the safety profile remained consistent with earlier studies and that no new safety signals were identified through week 24. That is reassuring for development, but it is not equivalent to regulatory confirmation of a favourable label. Longer exposure, larger patient numbers and post-approval surveillance would be required to establish how the medicine performs in routine clinical use.

The commercial question will be whether regulators require warnings, laboratory monitoring or restrictions that reduce the convenience advantage of a once-daily pill. A straightforward label could support broad adoption. More demanding monitoring or safety language could make established biologics or other oral therapies more competitive.

Why is zasocitinib strategically important to Takeda’s late-decade growth plan?

Takeda acquired the program from Nimbus Therapeutics in a transaction that included approximately $4 billion upfront and two potential $1 billion milestone payments. Those milestones become payable if products from the program achieve annual net sales thresholds of $4 billion and $5 billion.

The transaction economics illustrate the scale of Takeda’s expectations. Management has identified a potential peak annual sales range of $3 billion to $6 billion for zasocitinib, subject to approval and commercial success. Reaching the upper end would require substantial penetration in plaque psoriasis and likely expansion into additional immune-mediated diseases.

Zasocitinib is already being evaluated in Phase 3 studies for psoriatic arthritis and Phase 2 studies covering Crohn’s disease, ulcerative colitis, vitiligo and hidradenitis suppurativa. Positive results across multiple indications could spread the acquisition cost over a much larger revenue base. Conversely, a narrower psoriasis-only opportunity would make the return on Takeda’s upfront investment more dependent on pricing, market share and treatment duration.

The program also arrives as Takeda manages loss-of-exclusivity pressure across its mature portfolio and prepares for eventual patent erosion affecting Entyvio later in the decade. Fiscal 2025 revenue declined 1.7% to ¥4.506 trillion, although reported operating profit increased 19.3% to ¥408.8 billion and core operating profit reached ¥1.173 trillion. Adjusted free cash flow was ¥684.5 billion.

For fiscal 2026, Takeda forecasts ¥4.640 trillion in revenue and ¥420 billion in reported operating profit. Its constant-currency management guidance nevertheless calls for a low-single-digit decline in core revenue, a 5% to 8% reduction in core operating profit and a mid-teens decline in core earnings per share. Successful launches are therefore central to improving the company’s medium-term growth profile, but near-term launch expenditure will also place pressure on earnings.

Which regulatory and commercial hurdles remain before a potential psoriasis launch?

Takeda plans to begin filing applications with the United States Food and Drug Administration and other regulatory authorities during fiscal 2026. A planned filing is not an approval, and the July analysis does not change that distinction. Regulators must review efficacy, safety, manufacturing controls and the overall benefit-risk profile before zasocitinib can be marketed.

The immediate regulatory question is whether the difficult-site data contribute to the product label or primarily support medical and commercial communication after approval. The primary endpoints will remain central to the review, while the head-to-head deucravacitinib study could become more important for competitive positioning than for the initial approval decision.

Market access presents a separate challenge. Payers may require patients to try lower-cost systemic medicines before covering a newer branded therapy. Takeda will need to demonstrate that improved clearance can reduce treatment switching, improve persistence or produce measurable quality-of-life benefits that justify the expected price.

Physician familiarity and patient preference could support adoption, particularly among people reluctant to begin injectable therapy. Nevertheless, oral convenience is not sufficient on its own. Launch performance will depend on the final label, reimbursement coverage, formulary positioning, commercial execution and whether the efficacy seen in controlled trials persists in broader patient populations.

How did Takeda shares react as investors weighed another positive zasocitinib dataset?

Takeda’s New York-listed American depositary receipts closed at $16.64 on July 16, approximately 1.2% above the previous close. The movement coincided with the new presentation, although it cannot be attributed solely to the secondary endpoint announcement.

The shares were little changed over the preceding five trading sessions but about 6% above their June 16 close. At $16.64, Takeda remained within a 52-week range of $12.99 to $18.90, with an equity market value of approximately $52 billion.

The limited reaction is understandable because the pivotal trials had already succeeded and the latest findings did not constitute a new primary endpoint readout. The data improve the clinical and commercial narrative without materially changing the remaining regulatory timetable.

The next measurable proof points are the start of regulatory submissions, complete disclosure of the LATITUDE Atlas head-to-head results and clarity on the safety and monitoring language sought by regulators. Approval with a competitive label would strengthen the case that Takeda acquired a multibillion-dollar growth asset. Delays, restrictive labelling, weaker payer access or difficulty converting trial efficacy into prescribing share would weaken that thesis.

What are the key takeaways from Takeda’s difficult-site Phase 3 psoriasis results?

• Zasocitinib produced clear or almost clear scalp response rates of 77% and 74% at week 16.
• Palmoplantar response rates reached 71% and 69%, compared with 44% and 43% for apremilast.
• Nail psoriasis improved significantly versus placebo, although the absolute NAPSI change was not disclosed.
• Responses at difficult and high-impact sites were sustained through week 24 in both pivotal studies.
• The findings extend zasocitinib’s efficacy case beyond conventional whole-body PASI measures.
• Separate head-to-head results against deucravacitinib could strengthen Takeda’s position in the oral TYK2 market.
• Takeda reported no new safety signals, but regulatory review will determine the final warnings and monitoring requirements.
• Management’s $3 billion to $6 billion peak-sales expectation requires successful approval, access and potentially multiple indications.
• Regulatory submissions are planned to begin in fiscal 2026, with no approval yet granted.
• The next decisive evidence will be the full comparator dataset, regulatory progress and the eventual commercial label.